Winstrol 10mg 50tabs

Winstrol 10mg (Stanozolol) 50 Tablets | iRoids Pharma

Winstrol 10mg is an oral anabolic steroid containing 10mg of Stanozolol per tablet, available in packs of 50 tablets. At iRoids Pharma, we carry Winstrol 10mg as part of our oral anabolic steroid inventory for customers in markets where Stanozolol is legally available.

Stanozolol is the active compound in this preparation, universally recognized under the brand name Winstrol. It is a synthetic anabolic-androgenic steroid derived from Dihydrotestosterone with a documented clinical history spanning several decades, active FDA approval for hereditary angioedema, and one of the most extensively discussed pharmacological profiles among non-aromatizing oral anabolic steroids in performance communities globally.

The 10mg tablet format of this preparation represents the most conservative per-tablet concentration among the standard non-prescription Stanozolol oral formats available in the market. This conservative concentration carries specific pharmacological and practical implications that distinguish the 10mg format from higher-concentration non-prescription Stanozolol formats. This page covers the pharmacology, concentration-specific considerations, clinical background, and health and legal context relevant to anyone researching Stanozolol at iRoids Pharma. It does not constitute medical advice, recommend steroid use, or provide dosage, cycle, or stacking guidance of any kind.

Product Specifications

Stanozolol and the Winstrol Name: What This Preparation Contains

Stanozolol is the active compound in every preparation marketed under the Winstrol brand name or any of its generic equivalents. Winstrol was the original brand name under which Sterling Drug introduced Stanozolol to clinical markets in 1962. The Winstrol brand name has since become the most universally recognized designation for Stanozolol in performance communities globally, used interchangeably with the generic compound name across both clinical and non-clinical discussions.

The iRoids Pharma Winstrol 10mg preparation contains Stanozolol as its sole active compound at 10mg per tablet. The pharmacological profile, side effect considerations, and legal status associated with any discussion of Winstrol in clinical or performance community literature consequently apply directly and completely to this preparation. This nomenclature clarity is relevant because buyers researching this compound across different sources will encounter both the Winstrol brand name and the Stanozolol generic designation and should understand that both names refer to the identical pharmacological entity.

The 10mg Format: Concentration-Specific Context

The 10mg per tablet concentration of this iRoids Pharma preparation carries specific significance within both the Stanozolol clinical reference framework and the non-prescription market context for this compound.

Historical Pharmaceutical Reference

Pharmaceutical grade Winstrol tablets produced during the compound’s period of clinical availability were produced at 2mg per tablet for clinical use in hereditary angioedema management. The 10mg concentration consequently exceeds the historical pharmaceutical clinical tablet format by five times. However, the 10mg format sits at the lower end of the standard non-prescription Stanozolol oral tablet range, where concentrations commonly available include 10mg, 20mg, and 50mg per tablet formats.

Most Conservative Non-Prescription Format

The 10mg format represents the most conservative per-tablet concentration available in the standard non-prescription Stanozolol oral market. Every dose-dependent pharmacological effect including anabolic receptor activation, androgenic activity, adverse lipid effects, and hepatotoxicity is consequently less pronounced per tablet at the 10mg concentration than at any higher non-prescription Stanozolol format. This makes the 10mg format the entry-level concentration within the iRoids Pharma Winstrol oral product range.

50 Tablet Pack Context

Each pack contains 50 tablets at 10mg per tablet, providing a total of 500mg of active Stanozolol per pack. This pack size provides a meaningful supply for research purposes in markets where Stanozolol is legally available. The conservative 10mg per tablet concentration means the total pack supply of 500mg represents a more moderate total active compound delivery compared to higher-concentration pack configurations providing the same tablet count.

Comparison With Higher Concentration Formats

Non-prescription Stanozolol oral formats at 20mg and 50mg per tablet deliver double and five times the active compound per tablet respectively compared to this 10mg preparation. Every dose-dependent consideration is proportionally more pronounced per tablet at those higher concentrations. The 10mg format consequently provides the most favorable per-tablet side effect profile available within the oral Stanozolol non-prescription market.

What Is Stanozolol

Stanozolol is a synthetic anabolic-androgenic steroid derived from Dihydrotestosterone. Sterling Drug developed it in 1962 and introduced it to clinical markets under the Winstrol brand name. From its introduction, Stanozolol demonstrated a distinct pharmacological profile that separated it from most other oral anabolic steroids through its non-aromatizing characteristic and its structural modification of the DHT base.

Structurally, Stanozolol is a modified form of DHT with two key structural changes. A methyl group at the 17-alpha position allows it to survive first-pass liver metabolism when taken orally. A pyrazole ring fused to the A-ring of the steroid structure further modifies its pharmacological profile, increasing its anabolic activity and reducing its androgenic activity relative to testosterone. These structural modifications produce an oral anabolic steroid with an anabolic rating of 320 and an androgenic rating of 30 relative to a testosterone baseline of 100.

The compound does not aromatize to estrogen through any pathway. As a DHT derivative, it is structurally incompatible with the aromatase enzyme and consequently cannot undergo conversion to estradiol. Estrogenic side effects including water retention and gynecomastia are therefore not part of its direct pharmacological profile, which distinguishes it from testosterone and many other anabolic steroids where estrogenic conversion is a primary side effect consideration.

How Stanozolol Works

Stanozolol reaches systemic circulation in active form following oral administration due to the hepatic protection provided by 17-alpha alkylation. It subsequently interacts with biological systems through several distinct pharmacological mechanisms.

Androgen Receptor Binding

Stanozolol binds to androgen receptors throughout the body with an androgenic rating of 30 relative to testosterone’s baseline of 100. This comparatively low androgenic rating reflects reduced androgenic receptor affinity in non-target tissues despite meaningful anabolic receptor activation in muscle tissue. As a result, androgen receptor activation in skeletal muscle drives its anabolic effects while producing comparatively lower androgenic activity in androgen-sensitive tissues than testosterone-based compounds.

Nitrogen Retention

Stanozolol produces positive nitrogen retention in muscle tissue. The body retains more nitrogen than it excretes, consequently supporting an anabolic environment that favors muscle repair and preservation. This mechanism contributes to the lean mass maintenance observations consistently discussed in performance community literature on Stanozolol use.

Protein Synthesis

Stanozolol accelerates protein synthesis in skeletal muscle tissue through androgen receptor-mediated mechanisms. Faster protein synthesis supports muscle repair and maintenance. This mechanism is directly tied to its anabolic receptor activity and contributes to the lean tissue preservation effects associated with Stanozolol use.

No Aromatization

Stanozolol does not convert to estrogen through the aromatase enzyme pathway. As a DHT derivative, its structural incompatibility with aromatase means it cannot undergo enzymatic conversion to estradiol. Estrogenic side effects are consequently not part of its direct pharmacological profile at any concentration including the 10mg format.

SHBG Binding

Stanozolol carries documented affinity for Sex Hormone-Binding Globulin and reduces SHBG levels, increasing the proportion of other androgens circulating in free, biologically active form. This SHBG binding mechanism is one of the more pharmacologically interesting secondary characteristics of Stanozolol in performance community discussions and distinguishes it from many other anabolic steroids that do not meaningfully affect SHBG levels.

Collagen Synthesis Effects

Unlike many anabolic steroids, Stanozolol has been associated with decreased collagen synthesis in some research contexts. This effect distinguishes it from compounds like Nandrolone Decanoate that stimulate collagen synthesis. The implications of this characteristic for connective tissue health are consequently relevant to anyone researching Stanozolol for extended use and contribute to the joint discomfort observations consistently reported with Stanozolol use in performance community discussions.

Clinical Background

Stanozolol carries a documented clinical history that provides relevant context for its pharmacological profile.

FDA Approval for Hereditary Angioedema

The FDA approved Stanozolol for the prophylactic treatment of hereditary angioedema, a condition involving recurrent episodes of severe swelling affecting the face, extremities, genitalia, bowel, and throat. Stanozolol reduces the frequency and severity of these episodes through its effects on complement system proteins. This FDA approval consequently distinguishes Stanozolol from most anabolic steroids discussed in performance communities that carry no approved clinical indication. The 2mg pharmaceutical tablet format used in hereditary angioedema treatment consequently provides a relevant clinical pharmacological reference for Stanozolol’s mechanism of action despite the significant concentration difference from the 10mg non-prescription format.

Historical Clinical Applications

Stanozolol was historically used in several clinical contexts including treatment of anemia, muscle wasting conditions, and osteoporosis in various markets. These historical applications reflect its documented anabolic properties and relatively low androgenic activity compared to testosterone-based compounds. This clinical history provides a broader pharmacological research context for understanding its effects on nitrogen balance, protein metabolism, and tissue anabolism.

High-Profile Doping History

Stanozolol has been involved in several of the most widely publicized doping cases in competitive sports history. This documented doping history is directly relevant to understanding its pharmacological reputation in performance communities and provides context for its continued presence on WADA prohibited lists across all competitive sport categories.

Stanozolol at iRoids Pharma: How the 10mg Format Compares

Versus Stanozolol 25mg Pro Winstrol at NexorinPharma

The Pro Winstrol 25mg preparation available at NexorinPharma delivers two and a half times the active Stanozolol compound per tablet compared to the iRoids Pharma 10mg format. Both preparations contain the same active Stanozolol compound with identical pharmacological profiles. Every dose-dependent pharmacological effect and side effect is consequently two and a half times more pronounced per tablet at the 25mg concentration. The 10mg format at iRoids Pharma provides greater per-tablet dose precision and more conservative per-tablet pharmacological activity than the 25mg format.

Versus Methandienone 20mg at iRoids Pharma

Methandienone 20mg is a 17-alpha alkylated oral anabolic steroid that aromatizes significantly to estrogen. Stanozolol 10mg, by contrast, does not aromatize through any pathway. Both compounds are 17-alpha alkylated with significant hepatotoxicity. Stanozolol’s non-aromatizing profile produces a fundamentally different estrogenic side effect consideration than Methandienone. As a result, these two compounds carry different but not necessarily directly comparable side effect profiles despite both being hepatotoxic 17-alpha alkylated oral anabolic steroids.

Versus Oxandrolone 10mg at iRoids Pharma

Both Stanozolol 10mg and Oxandrolone 10mg are non-aromatizing 17-alpha alkylated oral anabolic steroids at the same milligram concentration. Oxandrolone carries active FDA approval for multiple clinical indications and a milder liver toxicity profile than Stanozolol. Stanozolol produces more pronounced adverse lipid effects than Oxandrolone and carries more significant hepatotoxicity. Stanozolol additionally produces the collagen synthesis reduction and associated joint discomfort that Oxandrolone does not. These distinctions place Stanozolol 10mg in a more aggressive side effect category than Oxandrolone 10mg despite their shared non-aromatizing characteristic and identical milligram concentration.

Versus Mesterolone 25mg at iRoids Pharma

Mesterolone 25mg is a non-17-alpha alkylated oral androgen with low hepatotoxicity, mild aromatase inhibition, SHBG binding, and minimal HPG suppression. Stanozolol 10mg is a 17-alpha alkylated oral anabolic steroid with significant hepatotoxicity, no anti-estrogenic properties beyond its non-aromatizing characteristic, and meaningful HPG suppression. These two compounds carry fundamentally different pharmacological profiles and serve different primary roles in oral androgen discussions at iRoids Pharma.

Versus Fluoxymesterone 5mg at iRoids Pharma

Fluoxymesterone 5mg carries an anabolic rating of 1900 and androgenic rating of 1600 with severe hepatotoxicity, pronounced CNS stimulatory effects, and extreme per-milligram potency. Stanozolol 10mg carries an anabolic rating of 320 and androgenic rating of 30 with significant but comparatively less severe hepatotoxicity and no meaningful CNS stimulatory effects. These two compounds consequently represent vastly different pharmacological potency levels and side effect severity profiles despite both being non-aromatizing 17-alpha alkylated oral androgens.

Side Effects and Health Risks

Stanozolol 10mg carries a well-documented side effect profile based on decades of clinical observations and research literature. The 10mg concentration represents the most conservative standard non-prescription oral Stanozolol format. Every dose-dependent consideration is consequently less pronounced per tablet than at higher concentration formats. These risks remain real and cannot be minimized in any responsible discussion of this compound.

Liver Toxicity

Liver toxicity is the most serious health concern associated with Stanozolol use at any concentration. The 17-alpha alkylation that enables oral bioavailability places significant and direct stress on liver tissue. Stanozolol’s hepatotoxicity is considered more clinically significant than Oxandrolone’s but generally comparable to Methandrostenolone among commonly discussed oral anabolic steroids. Elevated liver enzymes and in cases of prolonged or high-dose use more serious hepatic complications are documented in clinical literature and case reports. At the 10mg concentration, liver stress is less pronounced per tablet than at higher formats. Regular liver enzyme monitoring through biochemical testing is consequently essential for anyone using this compound at any concentration.

Adverse Lipid Effects

Stanozolol produces significant adverse effects on the lipid profile. It is consistently documented as one of the most pronounced lipid-affecting oral anabolic steroids in the clinical literature. HDL cholesterol drops dramatically while LDL cholesterol increases substantially. These lipid changes carry serious long-term cardiovascular health implications and are more pronounced with Stanozolol than with most other oral anabolic steroids. At the 10mg concentration, these lipid effects are less pronounced per tablet than at higher Stanozolol formats. However, regular cardiovascular monitoring is consequently absolutely essential for anyone using this compound.

Joint and Connective Tissue Effects

Stanozolol use is consistently associated with joint pain, dryness, and discomfort in performance community discussions. This characteristic relates to its effects on collagen synthesis and the absence of estrogenic water retention that normally provides some joint lubrication. The reduction in collagen synthesis combined with the absence of estrogenic effects produces the joint discomfort observations consistently reported with Stanozolol use. These effects are among the most practically significant side effect considerations with this specific compound and apply at any concentration including the 10mg format.

Androgenic Effects

Despite its low androgenic rating of 30, Stanozolol still produces androgenic side effects in susceptible individuals. Accelerated hair loss in genetically predisposed individuals and acne are the most consistently reported androgenic effects. In women, virilization effects including voice deepening and changes in body hair distribution are serious considerations even at the 10mg concentration.

Hormonal Suppression

Stanozolol suppresses the hypothalamic-pituitary-gonadal axis and the body’s natural testosterone production. Post-use hormonal disruption can persist for months. In some cases it results in long-term hypogonadism requiring medical treatment. Hormonal monitoring is consequently a relevant health consideration for anyone using this compound.

Psychological Effects

Anabolic steroid use carries documented associations with mood changes and irritability. These considerations apply to Stanozolol use at any concentration and are relevant health considerations for anyone using this compound over extended periods.

Legal and Regulatory Status

Stanozolol carries active FDA approval for hereditary angioedema under the Winstrol brand name. Outside of this approved indication, it carries Schedule III controlled substance status in the United States. Possession without a valid prescription is consequently a federal offense.

In the United Kingdom, Stanozolol falls under Class C of the Misuse of Drugs Act. Supply without authorization is a criminal offense.

The World Anti-Doping Agency bans Stanozolol alongside all major athletic governing bodies. It has been involved in several high-profile doping cases in competitive sports history and consequently appears on prohibited substance lists across Olympic sports, professional athletics, and competitive bodybuilding organizations that conduct testing.

You are responsible for confirming the legal status of Stanozolol in your specific jurisdiction before purchasing from iRoids Pharma.

Frequently Asked Questions

Is Winstrol 10mg Available at iRoids Pharma

Yes. iRoids Pharma carries Winstrol 10mg in packs of 50 tablets for customers in markets where Stanozolol is legally available. Visit iroidspharma.com to check current availability and pricing.

What Is the Half-Life of Stanozolol

Stanozolol produces a half-life of approximately 9 hours. Regular daily administration is consequently required to maintain stable plasma concentrations throughout the day. This pharmacokinetic characteristic applies across all oral Stanozolol concentration formats.

How Many Tablets Are in Each Pack

Each iRoids Pharma Winstrol 10mg pack contains 50 tablets at 10mg per tablet, providing a total of 500mg of active Stanozolol per pack.

Does Stanozolol Aromatize

No. Stanozolol does not convert to estrogen through the aromatase enzyme pathway. As a DHT derivative, it is structurally incompatible with aromatase and cannot undergo enzymatic conversion to estradiol. Estrogenic side effects are consequently not part of its direct pharmacological profile at any concentration.

Why Does Stanozolol Cause Joint Pain

Stanozolol use is associated with joint pain and discomfort. This characteristic relates to its effects on collagen synthesis and the absence of estrogenic water retention that normally provides some joint lubrication. The reduction in collagen synthesis combined with the absence of estrogenic fluid retention produces the joint discomfort observations consistently reported with Stanozolol use at any concentration.

How Does the 10mg Format Compare to Higher Concentration Stanozolol Formats

The 10mg format represents the most conservative per-tablet concentration in the standard non-prescription oral Stanozolol market. Non-prescription formats at 20mg and 50mg deliver double and five times the active compound per tablet respectively. Every dose-dependent pharmacological effect and side effect is consequently proportionally more pronounced per tablet at higher concentration formats. The 10mg format provides the most favorable per-tablet side effect profile available within the oral Stanozolol non-prescription market.

What Are the Most Serious Health Risks

Liver toxicity from 17-alpha alkylation and severe adverse lipid changes are the most serious health concerns with Stanozolol at any concentration. Joint and connective tissue effects from collagen synthesis reduction, hormonal suppression, androgenic effects, and cardiovascular implications from lipid dysregulation complete the primary risk profile. Medical supervision and regular blood work monitoring are consequently essential for anyone using this compound.

Is Winstrol 10mg Legal to Purchase

Stanozolol carries Schedule III controlled substance status in the United States outside of its approved hereditary angioedema indication. Legal status varies by jurisdiction. You are consequently responsible for confirming the legal status in your jurisdiction before purchasing from iRoids Pharma.

What to Consider Before Purchasing Winstrol 10mg

Stanozolol has active FDA approval for hereditary angioedema and a documented clinical history across several historical indications. This background provides a meaningful pharmacological research context for understanding its mechanisms and risk profile. The 10mg format at iRoids Pharma represents the most conservative per-tablet concentration available in the standard non-prescription oral Stanozolol market. Every dose-dependent pharmacological consideration is consequently less pronounced per tablet than at any higher non-prescription format.

The iRoids Pharma non-prescription preparation does not carry the manufacturing oversight of pharmaceutical grade Winstrol. The clinical research base applies to the pharmacological and risk profile of the active compound regardless of the specific manufacturer. Manufacturing standards and quality verification consequently differ between pharmaceutical grade and non-prescription preparations.

Stanozolol carries documented liver toxicity, adverse lipid effects, joint and connective tissue considerations, hormonal suppression, androgenic effects, and cardiovascular health risks. These risks require medical supervision to manage responsibly. Regular blood work monitoring including liver enzymes, lipid panels, and hormone levels is consequently essential for anyone using this compound at any concentration.

For customers in markets where Stanozolol is legally available, visit iroidspharma.com to check current Winstrol 10mg availability, pricing, and stock levels.